newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product